Pharming Group N.V.

Pharming sells into the rare-disease treatment ecosystem, where demand is driven by specialist physicians, hospitals, and treatment centers managing complex genetic or immunological disorders. Patients ultimately receive the therapies through healthcare providers and reimbursing payers, so access and diagnosis are important commercial drivers. The company also depends on healthcare systems and pharmacies that support specialty-drug distribution.

Pharming’s strategy centers on building and commercializing a portfolio of rare-disease medicines, with a focus on expanding use of RUCONEST® and Joenja® and broadening its therapeutic reach. The business also relies on maintaining regulatory, clinical, and commercial execution in multiple markets, where patient identification and reimbursement are key to growth. Portfolio expansion through biologics and small molecules supports longer-term diversification beyond a single product.